ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced additional data from preclinical studies on the anti-tumor effects of RX-3117, a next generation cancer cell specific nucleoside analog. In the study, oral administration of RX-3117 inhibited tumor growth in 12 different human cancer xenograft models including colon, non-small cell lung, small cell lung, pancreatic, renal, ovarian, and cervical cancer. In addition, RX-3117 inhibited the growth of human cancer cells lines shown to be resistant to the anti-cancer effects of gemcitabine, including in the primary low-passage human pancreatic tumorgraft model.
Help employers find you! Check out all the jobs and post your resume.
